ENDRA Life Sciences has commercialized an enhanced ultrasound technology for the pre-clinical research market and are leveraging that expertise to develop technology for increasing the capabilities of clinical diagnostic ultrasound, to broaden patient access to the safe diagnosis and treatment of a number of significant medical conditions in circumstances where expensive X-ray computed tomography, or CT, and magnetic resonance imaging, or MRI, technology is unavailable or impractical. Our firm represented National Securities Corporation and Dougherty & Company as the underwriters in the offering.
May 2017
ENDRA Life Sciences Inc. Completes IPO
Lead Contacts
